BPC-157 vs TB-500: Molecular Targets and Published Research Compared

BPC-157 has no identified receptor; TB-500 names two molecules with a known actin-binding partner. One rat study compared them directly.

By Updated

These two peptides are almost always named together, and the pairing conceals how differently the two are characterised. One has a binding partner mapped residue by residue in cell-free biochemistry. The other has no identified receptor at all, and its published mechanism is a list of pathways observed after exposure rather than an account of a binding event.

There is also a naming problem on one side of the comparison that has to be settled before anything can be compared, because "TB-500" refers to two different molecules.

What they are

PropertyBPC-157TB-500 (Thymosin β4)
Development codePL 14736 / PLD-116 (Pliva); PCO-02, Bepecin (PharmaCotherapia)RGN-259 (ophthalmic solution), RGN-352 (intravenous), RGN-137 (topical gel), NL005 (recombinant)
Compound typeSynthetic peptideSynthetic peptide
Peptide familyGastric pentadecapeptide; described in the literature as a partial sequence of body protection compound isolated from human gastric juiceβ-thymosin family; WH2 (WASP-homology 2) actin-binding module
Primary targetNot establishedMonomeric (G-)actin
Secondary targetsNot establishedPINCH / integrin-linked kinase complex (reported in cardiomyocytes)
Receptor familyNot establishedNot established
Agonist / antagonistNot establishedNot a receptor ligand; sequesters monomeric actin through a WH2-family binding module
Highest research phasePhase 1 registered (2015, no results posted); a phase 2 trial registered in 2026 is recruitingPhase 3 (thymosin beta-4 ophthalmic solution, completed); phase 1/2 (TB-500 fragment, recruiting)
Regulatory status (United States)Not approved. BPC-157 has not been approved by the U.S. Food and Drug Administration for any indication, and no pharmaceutical-grade formulation of it has been developed or validated.Not approved. Neither thymosin beta-4 nor the TB-500 fragment has been approved by the U.S. Food and Drug Administration for any indication.
Human trials publishedYesYes

Every value in this table is read from the two compounds’ own library entries when the site is built, so it cannot disagree with them. Nothing here ranks one compound against the other.

BPC-157 is a synthetic fifteen-residue peptide, sequence GEPPPGKPADDAGLV, described in the literature as a partial sequence of a protein fraction isolated from human gastric juice. Its published evidence base is overwhelmingly rodent. It is not approved by the U.S. Food and Drug Administration for any indication.

TB-500 is a name applied to two distinct molecules. The first is thymosin β4, a 43-residue intracellular actin-binding protein that occurs naturally and has been studied in clinical trials under that name. The second is Ac-LKKTETQ, a seven-residue fragment of it, which is what the chemical registers carry under the name TB-500. Neither is approved by the FDA for any indication.

That distinction is not pedantry, and it governs how the research on the right-hand side of this page reads. Much of what is cited for "TB-500" is research on the 43-residue protein. Whether it transfers to the seven-residue fragment is an empirical question with a partial and mostly negative answer, set out in the in vitro section below.

Receptor and mechanistic differences

TB-500 / thymosin β4 has a known binding partner. β-thymosins bind monomeric G-actin at a one-to-one ratio and hold it out of the filament pool. They are buffers rather than enzymes: they catalyse nothing, and their effect scales with how much of them is present. A separate reported mechanism does not involve actin at all — complex formation with PINCH and integrin-linked kinase, leading to Akt activation, which is the pathway invoked in the cardiac literature [5].

Two consequences follow. The site of action is inside the cell, which leaves open how a peptide applied outside a cell produces effects attributed to an intracellular partner. And activity belongs to a specific structural arrangement rather than to the sequence as a whole, so a fragment is not automatically a miniature of the parent.

BPC-157 has no identified target. No receptor has been reported, no binding affinity at any characterised target, no receptor family and no agonist or antagonist classification. Every published mechanistic claim has the form "after exposure to the peptide, this pathway was more active", and the pathways named most consistently are vascular endothelial growth factor receptor 2 signalling, nitric oxide synthesis, focal adhesion signalling in fibroblasts, and growth hormone receptor expression [13, 9, 10].

A second unresolved problem sits underneath the BPC-157 literature. A formal preclinical absorption, distribution, metabolism and excretion study in two species reports a plasma half-life under 30 minutes with approximately linear kinetics and intramuscular bioavailability between 14% and 51% depending on species, while the effects described in rodent models persist for hours to days. That disconnect has not been explained, and the review that sets it out treats it as a central obstacle to development rather than a curiosity [18].

Identified molecular target
BPC-157 — none reported. TB-500 / thymosin β4 — monomeric G-actin, binding at a 1:1 ratio [1, 2].
Site of action
BPC-157 — unresolved. Thymosin β4 — intracellular, which is itself an unresolved point for extracellular administration.
Published mechanism
BPC-157 — downstream pathway observations only [9, 10, 13]. Thymosin β4 — direct biochemistry plus a separate PINCH/integrin-linked kinase route [5].
Sequence
BPC-157, fifteen residues. Thymosin β4, 43 residues; the fragment sold as TB-500, seven residues beginning at position 17.
Naming
One molecule for BPC-157. Two, under one name, for TB-500.

What the research compares

One direct comparison exists, and it is in rats.

A 2026 study in the rat Achilles tendon model is the only published head-to-head assessment of the two compounds [19]. It is reported in the animal section below, in detail, because its result is more specific than the way the two compounds are usually discussed together.

There is no human comparison, and there is almost no human evidence on one side at all. BPC-157 has no published controlled human trial. Two 2025 reviews reach that conclusion by different routes: a systematic review that screened 544 articles and included 36 studies, of which 35 were preclinical and one was a retrospective series of 12 patients, recording explicitly that no clinical safety data were found and classifying the evidence as level IV and V [15]; and a narrative review that identified three human pilot studies in total and concluded the compound should be considered investigational [16].

Thymosin β4, by contrast, has been through randomised placebo-controlled human trials — a phase 1 intravenous safety and pharmacokinetic study in healthy volunteers [8], and phase 2 ophthalmic trials with prespecified endpoints [11, 12]. Those trials studied the 43-residue protein, not the seven-residue fragment.

So the asymmetry runs in two directions at once. Human evidence exists on the TB-500 side but is about a different molecule from the one the name usually denotes in supplier listings; human evidence is effectively absent on the BPC-157 side.

What the animal research compares

Animal research

The head-to-head rat study

Thirty-two male Sprague-Dawley rats, each 12 weeks old and approximately 330 g, underwent standardised Achilles tendon transection and repair and were randomised to four groups of eight: control, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, and the two combined. Administration was intraperitoneal for four weeks after surgery, after which tendons were harvested for biomechanical testing or histological evaluation [19].

Maximum load to failure was higher in both peptide groups than in controls, reaching statistical significance only in the TB-500 group (p < 0.05). Total Bonar scores were significantly lower in the TB-500 group (p = 0.016), and total Movin scores were significantly lower in the TB-500 and combined groups (p = 0.017 and p = 0.040). The BPC-157 group showed numerically lower scores without reaching significance on total scores. Sirius red birefringence analysis showed increased type I collagen organisation and altered type III collagen distribution in the treatment groups, most markedly in the TB-500 group. Immunohistochemistry found no significant difference in type I collagen expression between groups, while type III collagen expression differed significantly [19].

The combination conferred no additional benefit over either agent alone. The authors offer convergence on shared downstream pathways as a possible explanation and state explicitly that the hypothesis requires further experimental confirmation [19].

Limitations. Eight rats per group, one model, one time point at four weeks, one administered amount per compound, and the two amounts differ six-fold — 10 against 60 µg/kg/day — so the comparison is between two specific regimens rather than between the compounds at equivalent exposure. The authors describe the study as exploratory and call for optimisation of the administered amount and longer follow-up. Nothing in it establishes anything about humans.

Each compound's separate animal record

The BPC-157 rodent literature is wide and concentrated. In the rat Achilles tendon-to-bone model, administration reported increased Achilles functional index values, increased load to failure, stiffness and Young's elasticity modulus, better collagen organisation and more type I collagen; 6α-methylprednisolone consistently worsened the same measures and the peptide substantially reduced that worsening [6]. The same group applied a comparable design to complete transection of the rat quadriceps [7]. In rat hind-limb ischaemia, blood-flow restoration was accelerated with increased vessel number and increased vascular VEGFR2 expression [13].

Two structural cautions apply to that body of work. The reported effects span picograms to micrograms per kilogram within the same experiment, without a concentration–response model that would explain the range. And the tendon and striated-tissue work comes predominantly from one group at the University of Zagreb School of Medicine, with thin independent replication.

The thymosin β4 animal literature is differently shaped. In full-thickness rat dermal wounds, topical or intraperitoneal administration increased re-epithelialisation by 42% over saline controls at four days and by as much as 61% at seven days, with treated wounds contracting at least 11% more by day seven [3]. In db/db diabetic mice and 26-month-old aged mice, thymosin β4 increased wound contracture and collagen deposition; critically, the authors also tested the seven-residue actin-binding domain LKKTETQ and reported that it promoted repair in the aged animals comparably to the parent molecule [4]. After coronary artery ligation in mice, administration up-regulated integrin-linked kinase and Akt activity, enhanced early myocyte survival and improved cardiac function [5].

Findings described in this section were observed in animals. Nothing in them establishes anything about humans.

What the in vitro research compares

In vitro research

This is where the two compounds are least alike, and where the fragment question on the TB-500 side is actually settled.

Thymosin β4 — biochemistry with a mapped site. Using the DNase I inhibition assay, thymosin β4 sequesters G-actin at a one-to-one ratio and blocks polymerisation in high-salt solution; oxidation of the single methionine at position 6 did not abolish the property. Two C-terminal fragments did: neither thymosin β4 13-43 nor 24-43 inhibited G-actin polymerisation at all, and the authors concluded that structural features before position 13 are obligatory [1]. Mapping by chemical synthesis, cross-linking, native-gel complex formation and circular dichroism placed the actin-binding site in two separate structural entities: an N-terminal part, residues 1 to 16, which must adopt an α-helix and contacts actin through a hydrophobic patch, and a hexapeptide motif at residues 17 to 22 [2].

The seven-residue peptide sold as TB-500 begins at residue 17. Residues 17 to 22 are genuinely part of the actin-binding site — but they are one of two parts, and removing the other abolished sequestration in the assay that measures it. So the fragment is not established as an actin sequestrant, whatever it may do in a dermal wound model [1, 4].

BPC-157 — pathway observations in cultured cells. In rat Achilles tendon explants and isolated tendon fibroblasts, exposure accelerated outgrowth and increased migration in proportion to concentration, while proliferation measured by MTT assay was unchanged; survival under hydrogen peroxide stress increased; phosphorylation of focal adhesion kinase and paxillin rose with concentration while total protein amounts were unaltered [9]. A cDNA microarray of rat tendon fibroblasts identified the growth hormone receptor among the most up-regulated genes, confirmed at mRNA and protein level, with growth hormone then increasing proliferation and activating Janus kinase 2 — an indirect mechanism, a change in sensitivity to a hormone rather than an action of the peptide itself [10]. In human vascular endothelial cells, exposure increased VEGFR2 mRNA and protein but not VEGF-A, and promoted receptor internalisation; internalisation, VEGFR2–Akt–eNOS activation and endothelial tube formation were all blocked by dynasore, an inhibitor of endocytosis [13].

More recent in vitro work has examined BPC-157 in human tissue directly: endothelium-dependent, nitric oxide-mediated vasorelaxant effects were reported in human internal mammary artery [17].

These are observations in cell-free assays and cultured cells. They describe biochemistry and establish nothing about animals or people.

What the human research shows for each

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

BPC-157: no published controlled human trial exists. The most informative published human-facing documents are the two 2025 reviews described above, which between them identify a retrospective series of 12 patients and three small pilot studies, and state that no clinical safety data were found [15, 16]. Three trials are registered: a phase 1 in healthy volunteers registered in 2015 with no posted results and status listed as unknown [20]; a randomised, double-blind, placebo-controlled phase 2 in acute hamstring strain with a planned enrolment of 120, recruiting from February 2026 [21]; and a randomised pilot in rotator cuff repair, planned enrolment 30, not yet recruiting [22]. A registered protocol is a statement of intent, not a result.

Thymosin β4 has been through randomised human trials, as the 43-residue protein. A phase 1 study administered single and multiple intravenous amounts to healthy volunteers and reported on safety and pharmacokinetics [8]. Two randomised placebo-controlled phase 2 ophthalmic trials reported prespecified endpoints in severe dry eye disease [11, 12], and a first-in-human phase 1 study of recombinant human thymosin β4 has also been published [14].

The two human records are not comparable, for two separate reasons. The first is volume: one side has randomised placebo-controlled trials and the other has none. The second is identity: the trials on the thymosin β4 side administered the full 43-residue protein, in ophthalmic or intravenous form, for indications unrelated to the ones the two compounds are usually discussed together for. They are not trials of the seven-residue fragment, and they cannot be read as such.

Research status of each

BPC-157 is investigational, with no approval anywhere, no identified receptor, and no completed controlled human trial. Two trials are recruiting or pending and one registered in 2015 has never reported [15, 16, 21, 22].

TB-500 is investigational under both readings of the name. Thymosin β4 has an ophthalmic clinical programme and published phase 1 and phase 2 results but no approval [8, 11]. The seven-residue fragment has one supportive animal result in a dermal model and a biochemical literature that places its central function outside the fragment's boundaries [4, 1].

Neither compound has an approved indication, and neither has a completed phase 3 programme. Where human trials exist, they studied pharmaceutical material manufactured to a regulatory standard and administered under a registered protocol under clinical supervision. None of that research is research into, or evidence about, research-grade material supplied for laboratory use.

Frequently Asked Questions

What is the difference between BPC-157 and TB-500?
How well each is characterised. TB-500 relates to thymosin β4, whose binding partner is known: β-thymosins bind monomeric G-actin at a one-to-one ratio, and the binding site has been mapped residue by residue [1, 2]. BPC-157 has no identified receptor and no reported binding affinity at any characterised target; its published mechanism consists of pathways observed to be more active after exposure [9, 10, 13].
Does TB-500 mean thymosin beta-4?
It refers to two different molecules, and the distinction changes what the research means. Thymosin β4 is a 43-residue intracellular actin-binding protein that has been studied in randomised human trials [8, 11]. Ac-LKKTETQ is a seven-residue fragment of it and is what the chemical registers carry under the name TB-500. Research on the protein does not automatically transfer to the fragment.
Have BPC-157 and TB-500 been compared in the same study?
Once, in rats. A 2026 study randomised 32 male Sprague-Dawley rats after standardised Achilles tendon transection and repair into four groups of eight — control, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, and both combined — administered intraperitoneally for four weeks [19]. There is no human comparison of the two.
What did that rat study report?
Maximum load to failure was higher in both peptide groups than in controls but reached statistical significance only in the TB-500 group (p < 0.05). Total Bonar scores were significantly lower in the TB-500 group (p = 0.016) and total Movin scores in the TB-500 and combined groups (p = 0.017 and p = 0.040); the BPC-157 group's total scores were numerically lower without reaching significance. The combination conferred no additional benefit over either agent alone [19]. The authors describe the study as exploratory. Eight animals per group at one time point with a six-fold difference between the two administered amounts is a comparison of two regimens, not of the compounds at equivalent exposure, and a finding in rats establishes nothing about humans.
Does either compound have human trial evidence?
Unevenly. There is no published controlled human trial of BPC-157; two 2025 reviews identified only a retrospective series of 12 patients and three small pilot studies, and recorded that no clinical safety data were found [15, 16]. Thymosin β4 has randomised placebo-controlled trials — a phase 1 intravenous safety and pharmacokinetic study [8] and phase 2 ophthalmic trials [11, 12] — but those studied the 43-residue protein, not the seven-residue fragment.
Is the seven-residue fragment an actin sequestrant?
Not on the biochemical evidence. The actin-binding site of thymosin β4 comprises two structural entities: an N-terminal region, residues 1 to 16, which must adopt an α-helix, and a hexapeptide motif at residues 17 to 22 [2]. Fragments lacking the N-terminal region did not inhibit G-actin polymerisation at all in the assay that measures sequestration [1]. The peptide sold as TB-500 begins at residue 17, so it carries one of the two parts.
Is either compound approved by the FDA?
No. Neither BPC-157 nor either molecule called TB-500 is approved by the U.S. Food and Drug Administration for any indication, and neither has completed a phase 3 programme.
What is the unresolved problem in the BPC-157 literature?
The gap between its residence time and the duration of the effects reported for it. A formal preclinical absorption, distribution, metabolism and excretion study in two species reports a plasma half-life under 30 minutes and intramuscular bioavailability between 14% and 51% depending on species, while effects described in rodent models persist for hours to days. The review that sets this out treats the disconnect as a central obstacle to development rather than a curiosity [18].

References

  1. Actin-sequestering ability of thymosin beta 4, thymosin beta 4 fragments, and thymosin beta 4-like peptides as assessed by the DNase I inhibition assay Biological Chemistry Hoppe-Seyler; 1993. PMID 8471179 doi:10.1515/bchm3.1993.374.1-6.117
  2. The actin binding site of thymosin beta 4 mapped by mutational analysis The EMBO Journal; 1996. PMID 8617195
  3. Thymosin beta4 accelerates wound healing The Journal of Investigative Dermatology; 1999. PMID 10469335 doi:10.1046/j.1523-1747.1999.00708.x
  4. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice Wound Repair and Regeneration; 2003. PMID 12581423 doi:10.1046/j.1524-475x.2003.11105.x
  5. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair Nature; 2004. PMID 15565145 doi:10.1038/nature03000
  6. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation Journal of Orthopaedic Research; 2006. PMID 16583442 doi:10.1002/jor.20096
  7. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157 Journal of Orthopaedic Research; 2006. PMID 16609979 doi:10.1002/jor.20089
  8. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers Annals of the New York Academy of Sciences; 2010. PMID 20536472 doi:10.1111/j.1749-6632.2010.05474.x
  9. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration Journal of Applied Physiology; 2011. PMID 21030672 doi:10.1152/japplphysiol.00945.2010
  10. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts Molecules; 2014. PMID 25415472 doi:10.3390/molecules191119066
  11. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial Cornea; 2015. PMID 25826322 doi:10.1097/ICO.0000000000000379
  12. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model Clinical Ophthalmology; 2015. PMID 26056426 doi:10.2147/OPTH.S80954
  13. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation Journal of Molecular Medicine; 2017. PMID 27847966 doi:10.1007/s00109-016-1488-y
  14. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers Journal of Cellular and Molecular Medicine; 2021. PMID 34346165 doi:10.1111/jcmm.16693
  15. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review HSS Journal; 2025. PMID 40756949 doi:10.1177/15563316251355551
  16. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine; 2025. PMID 40789979 doi:10.1007/s12178-025-09990-7
  17. Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery Journal of Clinical Medicine; 2026. PMID 42123221 doi:10.3390/jcm15093488
  18. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Pharmaceutics; 2026. PMID 42198317 doi:10.3390/pharmaceutics18050625
  19. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Joint Diseases and Related Surgery; 2026. PMID 42542926 doi:10.52312/jdrs.2026.2951
  20. PCO-02 - Safety and Pharmacokinetics Trial. NCT02637284
  21. BPC 157 for Acute Hamstring Muscle Strain Repair. NCT07437547
  22. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery. NCT07803250

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.